About: The broad-spectrum antiviral recommendations for drug discovery against COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The broad-spectrum antiviral recommendations for drug discovery against COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The broad-spectrum antiviral recommendations for drug discovery against COVID-19
Creator	Naeem, Muhammad Abbas, Faheem Bano, Saira Farman, Muhammad Hazafa, Abu Jahan, Nazish Mumtaz, Muhammad Naeem, Huma Sadiqa, Sania Ur-Rahman, Khalil
topic	covid:e7bb5d209bb3d45a4044a776c5fef2fa0663fb00#this
source	Medline; PMC
abstract	Despite to outbreaks of highly pathogenic beta and alpha coronaviruses including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and human coronavirus, the newly emerged 2019 coronavirus (COVID-19) is considered as a lethal zoonotic virus due to its deadly respiratory syndrome and high mortality rate among the human. Globally, more than 3,517,345 cases have been confirmed with 243,401 deaths due to Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19. The antiviral drug discovery activity is required to control the persistence of COVID-19 circulation and the potential of the future emergence of coronavirus. However, the present review aims to highlight the important antiviral approaches, including interferons, ribavirin, mycophenolic acids, ritonavir, lopinavir, inhibitors, and monoclonal antibodies (mAbs) to provoke the nonstructural proteins and deactivate the structural and essential host elements of the virus to control and treat the infection of COVID-19 by inhibiting the viral entry, viral RNA replication and suppressing the viral protein expression. Moreover, the present review investigates the epidemiology, diagnosis, structure, and replication of COVID-19 for better understanding. It is recommended that these proteases, inhibitors, and antibodies could be a good therapeutic option in drug discovery to control the newly emerged coronavirus. HIGHLIGHTS: COVID-19 has more than 79.5% identical sequence to SARS-CoV and a 96% identical sequence of the whole genome of bat coronaviruses. Acute respiratory distress syndrome (ARDS), renal failure, and septic shock are the possible clinical symptoms associated with COVID-19. Different antivirals, including interferons, ribavirin, lopinavir, and monoclonal antibodies (mAbs) could be the potent therapeutic agents against COVID-19. The initial clinical trials on hydroquinone in combination with azithromycin showed an admirable result in the reduction of COVID-19. The overexpression of inflammation response, cytokine dysregulation, and induction of apoptosis could be an well-organized factors to reduce the pathogenicity of COVID-19.
has issue date	2020-06-17(xsd:dateTime)
bibo:doi	10.1080/03602532.2020.1770782
bibo:pmid	32546018
has license	no-cc
sha1sum (hex)	e7bb5d209bb3d45a4044a776c5fef2fa0663fb00
schema:url	https://doi.org/10.1080/03602532.2020.1770782
resource representing a document's title	The broad-spectrum antiviral recommendations for drug discovery against COVID-19
has PubMed Central identifier	PMC7309307
has PubMed identifier	32546018
schema:publication	Drug Metab Rev
resource representing a document's body	covid:e7bb5d209bb3d45a4044a776c5fef2fa0663fb00#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/e7bb5d209bb3d45a4044a776c5fef2fa0663fb00
is schema:about of	named entity 'coronavirus' named entity 'zoonotic' named entity 'circulation' named entity 'pathogenic' named entity 'ritonavir' named entity 'lethal' named entity 'lopinavir' named entity 'protein expression' named entity 'emerged' named entity 'CAUSED BY' named entity '2019' named entity 'HAVE' named entity 'HUMAN CORONAVIRUS' named entity 'CIRCULATION' named entity 'CORONAVIRUSES' named entity 'ITS' named entity 'MORTALITY RATE' named entity 'NEWLY' named entity 'DEATHS' named entity 'PROTEIN EXPRESSION' named entity 'OPTION' named entity 'TREAT' named entity 'ACTIVITY' named entity 'IMPORTANT' named entity 'BETA' named entity 'AIMS' named entity 'RECOMMENDED' named entity 'MONOCLONAL ANTIBODIES' named entity 'EMERGENCE' named entity 'ALPHA' named entity 'INHIBITING' named entity 'coronavirus' named entity 'However' named entity 'persistence' named entity 'highly' named entity 'highlight' named entity 'COVID-19' named entity 'Despite' named entity 'viral protein' named entity 'ARDS' named entity 'MERS-CoV' named entity 'COVID' named entity 'caused by COVID-19' named entity 'monoclonal antibodies' named entity 'antiviral' named entity 'nonstructural proteins' named entity 'coronavirus' named entity 'mortality rate' named entity 'COVID' named entity 'protease' named entity 'vaccines' named entity 'kidney failure' named entity 'transcription' named entity 'ritonavir' named entity 'antivirals' named entity 'Achilles heel' named entity 'GS-5734' named entity 'HIV' named entity 'SARS-CoV' named entity 'Favipiravir' named entity 'vaccine against COVID-19' named entity 'Prof.' named entity 'virologic' named entity 'common cold' named entity 'virus replication' named entity 'IFN-a' named entity 'double-blinded' named entity 'coronaviruses' named entity 'MERS-CoV' named entity 'miR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software